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Abstract
Arterial hypertension is one of the main side effects of cyclosporin treatment and seems to be due to activation of the sympathetic nervous
system. Some authors hypothesized that cyclosporin may act on the sympathetic nervous endings increasing catecholamine release, in
agreement with our previous works which demonstrated an increase in rat plasma catecholamine levels after 30 mg/kg per day cyclosporin
treatment for 7 weeks. Therefore, the aim of this work was to study the cyclosporin mechanism responsible for that increase in plasma
catecholamines. Male Wistar rats were used. Noradrenaline release was performed in vitro experiments after loading rat aorta abdominal
segments with 3H-noradrenaline (3H-NA). The release of 3H-NA was measured after electrical stimulation in the presence of 10−6 M
cyclosporin. In another set of experiments electrical stimulation was replaced by a pulse addition of cyclosporin (10−6 M). Another group
of rats was treated with 30 mg/kg per day cyclosporin for 7 weeks and catecholamine contents in aorta abdominal segments and adrenals
were measured by high performance liquid chromatography system with electrochemical detection (HPLC-ECD). An increase in the
3H-NA release was observed in both types of in vitro experiments. Since cocaine abolished these cyclosporin effects, the obtained results
suggest that cyclosporin may act on the catecholamine transporter across the membrane. In addition, after the 7 weeks of cyclosporin
treatment, a significant decrease in catecholamine aorta contents was verified but in adrenals there was no difference regarding to controls.
However, the dopamine synthesis/degradation ratio measured by the DA/DOPAC ratio suggests an increase in dopamine synthesis. These
facts are in agreement with the enhanced plasma catecholamine levels and with the hypothesis of tissue catecholamine depletion. However,
they do not explain the increase in plasma adrenaline levels, since adrenaline is a reflex of adrenal activity. The synthesized dopamine in
adrenals seems to be unable to reach vesicles and to be metabolized in adrenaline. The observed decrease in HVA adrenal levels may be a
consequence of extraneuronal uptake inhibition or inhibition by cyclosporin of the direct o-methylation of DOPAC.
In conclusion, our results suggest that cyclosporin increases catecholamine release from the sympathetic nervous endings by a tyramine-
like effect, i.e. by acting directly on the catecholamine transporter of the membrane.
© 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Cyclosporin is an immunosuppressive drug that has con-
siderably improved the survival of transplant patients in
recent years. However, several side effects have been as-
sociated with cyclosporin treatment, such as hypertension,
nephrotoxicity and neurotoxicity. The possible mecha-
nisms underlying cyclosporin-induced hypertension were
reviewer by Sander and Victor [1]. Nevertheless, none of
the hypothesis is out of controversy. Thus, the only fact
that is in agreement with all of them is that cyclosporin
changes vascular reactivity. Concerning noradrenaline and
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phenilephrine-induced contraction, cyclosporin seems to
increase [2–5] or decrease [6–8] vessel contraction. To ex-
plain these facts Xue et al. [2] hypothesize that after an
inhibition of the 2, adrenoceptors cyclosporin increases
contraction by an increase of noradrenaline release from
the sympathetic nervous endings. Also Yaris and Tuncer
in 1995 [3], indicated cyclosporin as a possible  adreno-
ceptors inhibitor, after the observation that cyclosporin
increased noradrenaline levels more than those obtained
by electrical stimulation. Moreover, studies on plasma cat-
echolamine levels in human patients and animals treated
with cyclosporin have provided controversial results. In this
sense, Van den Dopel et al. [9] and Sehested et al. [10] found
no changes in plasma noradrenaline levels in patients with
kidney transplant and hypertension undergoing treatment
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with cyclosporin. In contrast, also in humans and under
similar conditions, Crum et al. [11] observed an increase
in plasma adrenaline and noradrenaline levels. Experiments
in cyclosporin-treated rats have also afforded conflicting
results. In a study following the administration of 5, 10
and 20 mg/kg per day cyclosporin for 3 weeks, Gerkens
[12] did not find any changes in plasma catecholamine lev-
els. However, Duruibe et al. [13] described an increase in
noradrenaline and adrenaline levels but not of dopamine.
More recently, our research group observed a significant
increase in rat plasma catecholamine levels (noradrenaline,
adrenaline and dopamine) after 7 weeks of treatment with
30 mg/kg per day cyclosporin—Sandimmune Neoral® [14].
As expected, these results were directly correlated with
cyclosporin-induced hypertension. The observed effect of
cyclosporin on plasma catecholamine levels may be due to
alterations in the sympathetic nerve endings of blood vessels,
promoted by the immunosuppressive drug. In the light of
these findings, the goal of the present work was to study the
effect of cyclosporin in the noradrenaline release from the
sympathetic nerve endings of blood vessels. We also stud-
ied the effect of cyclosporin treatment on the catecholamine
contents of rat abdominal aorta and adrenals in order to con-
tribute for a possible explanation of the changes in plasma
catecholamine levels and subsequent hypertension.
2. Material and methods
Male Wistar rats (weighing 300–350 g at the beginning
of experiments) were housed four to five per cage under a
12 h light/dark cycle in a room with controlled temperature
(22±1 ◦C), humidity (50±10%) with food and water avail-
able ad libitum. The experimental animals were handled as
carefully as possible in order to minimize environmental
stress. Animal experiments were carried out in agreement
with the European Convention on Animal Care, and the
whole research project in which these studies are included
received the approval of the Portuguese National Foundation
for Science and Technology.
2.1. Experimental procedure
The animals were randomized into two groups: Group I
was treated with 30 mg/kg cyclosporin and Group II received
only the solvent (control group). Rats were treated daily with
cyclosporin for a period of 7 weeks by oral administration.
The cyclosporin was the commercial formulation (Sandim-
mune Neoral®) dissolved in orange juice as indicated for
human treatment. Both groups received the same volume of
the drug or solvent (0.5 ml).
The cyclosporin dose used in vivo induced a blood con-
centration similar to that found in humans, as discussed
before [15]. Thus, cyclosporin blood levels measured in
our treated rats were 1.76 ± 0.06M and 0.43 ± 0.11M
at 14 and 36 h, respectively, after the last administration
of 30 mg/kg per day cyclosporin. Moreover, the 10−6 M
cyclosporin corresponds approximately to maximal plasma
values attained in human pharmacokinetics [16,17]. Based
on these results, a 10−6 M cyclosporin concentration was
used in all in vitro experiments.
2.2. Dissection and determination of monoamines
After the 7 weeks cyclosporin treatment the animals
were sacrificed by pentobarbital sodium overdose. The ab-
dominal segment of aorta as well as adrenals were rapidly
removed and cleaned from surrounding tissue. Small seg-
ments of abdominal aorta and adrenals were immediately
placed into 0.1 M perchloric acid (HClO4) solution and kept
overnight. Aliquots of the extract were directly injected
in a high performance liquid chromatography system with
electrochemical detection (HPLC-ECD).
The chromatographic system consisted of a Gilson Ap-
plied Chromatographic System with a 305 model pump and
a 231 injection valve model, with a 50l loop. A Biophase
ODS RP18 analytical column (250 × 4.6, Ø = 5m; Bio-
analytical Systems Inc., USA) was used and separation was
made possible by using an isocratic solvent system con-
sisting of an acetate–citrate buffer (sodium acetate 0.1 M,
citric acid 0.1 M), containing sodium octane sulfonate
(0.5 mM), Na2EDTA (0.15 mM), dibutylamine (1 mM) and
10% methanol. A flow rate of 1 ml/min was maintained and
detection of the chromatographed catecholamines achieved
by using a 141 Gilson electrochemical detector model
(650 mV).
2.3. Release of 3H-noradrenaline
2.3.1. Incubation with 3H-noradrenaline
The strips of abdominal aorta were immersed in a Krebs
physiologic solution of the following composition (which
was also used for superfusion); mmol/l: 118.67 NaCl; 5.36
KCl; 1.90 CaCl2; 0.67 NaH2PO4; 0.57 NaHCO3; 11.1 glu-
cose; pH 7.4. To avoid oxidation of noradrenaline, Na2EDTA
0.027 and ascorbic acid 0.057 mmol/l were added to the so-
lution which was maintained at 37 ◦C and bubbled with 95%
O2 and 5% CO2. Tissues were first exposed for 30 min to
pargyline (1 mmol/l) to inhibit monoamine oxidase (MAO),
and then incubated with 3H-noradrenaline (3H-NA) (for 1 h
in small beakers containing 5 ml medium with (−)-3H-NA
(0.23mol/l).
2.3.2. Spontaneously and electrically-induced release of
3H-noradrenaline
After incubation, the tissues were transferred into 1 ml
glass chambers and perfused with 3H-NA-free medium from
bottom to top at a rate of 0.8 ml/min. Two protocols were
performed.
2.3.2.1. Protocol 1: electrically-induced 3H-noradrenaline
release. After a washout period (of 75 min), the perfusion
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fluid was collected continuously, in 5-min samples, from
t = 75 min to t = 210 min (t = 0 being the start of per-
fusion). In order to assess the basal and electrically evoked
outflow of 3H-NA, 5-min period of transmural stimulation
(3 Hz, 1 ms, 100 V, 300 pulses, stimulator SD9B, Grass In-
struments, MA, USA) [from t = 110 min to t = 115 min
(S1); from t = 130 min to t = 135 min (S2); from
t = 150 min to t = 155 min (S3); from t = 170 min to
t = 175 min (S4); from t = 190 min to t = 195 min (S5)]
were performed. These experiments were done in the pres-
ence and absence of cyclosporin (10−6 M) and/or cocaine
(7.5×10−6 M). The drugs were placed into the bath 10 min
before S3 and maintained during the S4 and S5 periods.
Aliquots of each fraction collected were added to scintilla-
tion fluid (1:3), and the radioactivity measured in a Packard
2000 spectrometer provided with dpm correction. At the
end of the experiment the segments were removed from the
chambers, dried and heighted, and the amount of 3H-NA re-
tained measured. The stimulation-evoked overflow was ob-
tained by subtraction of the estimated basal outflow from the
total overflow in stimulation and poststimulation samples.
The evoked overflow was expressed as fractional release
per shock in relation to S2. To obtain the 3H-NA that was
retained in the vessel, dpm values were divided by segments
weight.
2.3.2.2. Protocol 2: spontaneously release of 3H-noradre-
naline. After a washout period (of 75 min), the perfusion
fluid was collected continuously, in 5-min samples, from
t = 75 min to t = 150 min (t = 0 being the start of
perfusion). The drugs were added from t = 110 min to
t = 115 min (E1) and from t = 130 min to t = 135 min
(E2) (cyclosporin 10−6 M; cocaine 7.5× 10−6 M; tyramine
5 × 10−5 M). Aliquots of each fraction were added to the
scintillation fluid (1:3), and the radioactivity measured in a
Packard 2000 spectrometer provided with dpm correction.
At the end of the experiment the segments were removed
from the chambers, dried and heighted and measured the
amount of 3H-NA retained.
After correction by vessel weight, values in each stimu-
lation point (E1 and E2) were calculated according to the
expression:




3H-NA (released in E)
3H-NA (total released)
+3H-NA (retained in the segment)

× 100
The amount of 3H-NA retained in the vessel was calcu-
lated according to the following expression:




total released + total in the vessel
)
× 100
2.4. Measurement of the radioactivity retained
in the vessel
The vascular segments were heat (100 ◦C in a dry bath)
with 200l H2O2 (30 vol.) plus 200l HClO4, 30% during
15 min. To the solubilized samples scintillation fluid was
added, and the radioactivity measured in a Packard 2000
spectrometer provided with dpm correction.
In both protocols using 3H-NA a HPLC-ECD control was
performed in order to determine that in the final of the ex-
periments we, in fact, measured noradrenaline and not other
substances like noradrenaline metabolites.
2.5. Preparation of cyclosporin
The majority of authors used ethanol to dissolve cy-
closporin. However, this solvent could have some undesired
effects. To avoid these pitfalls, we used dimethyl sulfoxide
(DMSO) as solvent. In all control experiments DMSO was
also added. The possible morphological-induced alterations
of this cyclosporin solution were tested in smooth muscle
cell cultures. DMSO (in the percentage used) showed no
effects on cell morphology or viability (data not showed).
2.6. Chemicals
Cyclosporin and Sandimmune Neoral® were supplied
by Novartis Farma, Portugal. [3H]-NA (specific activity =
12 Ci/mmol) was obtained from Amersham (USA). The
scintillation fluid (UNIVERSOL) was obtained from ICN
(Costa Mesa). All the other chemicals were obtained from
Sigma, St. Louis, MO, USA.
2.7. Statistics
Fisher’s protected least significant difference (PLSD) test
preceded by one-way ANOVA were applied. Probability lev-
els of less than 0.05 were regarded as statistically significant.
3. Results
In a previous published work we demonstrated that an
increase in plasma catecholamine levels was observed after
cyclosporin administration [14]. In those animals the in-
crease in plasma catecholamine levels was correlated with an
increase in blood pressure. Moreover, cyclosporin induced
arterial hypertension after the first week of treatment. Since
we hypothesize that the increase in plasma catecholamine
levels was due to a cyclosporin action on the vascular
sympathetic nervous endings, the aorta catecholamine con-
tents were measured in the present work. After 7 weeks of
30 mg/kg per day cyclosporin treatment, a significant de-
crease in catecholamine contents (noradrenaline, adrenaline
and dopamine) was observed in abdominal aorta segments
(Fig. 1). To further understand the cyclosporin effect on
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Fig. 1. Catecholamine contents in rat abdominal aorta segments after 7
weeks of treatment with solvent (control) (n = 10) or with CsA 30 mg/kg
per day (n = 12). Catecholamines [noradrenaline (NA), adrenaline (AD)
or dopamine (DA)] were determined by HPLC-ECD. Data shown are
means± S.E.M. ∗P < 0.05 related to control.
Table 1
Electrically-induced release of 3H-noradrenaline from rat aorta segments
Release fraction ratio Control Control + cocaine Cyclosporin Cyclosporin + cocaine
S3/S2 0.847 ± 0.042 0.974 ± 0.087 1.109 ± 0.093∗ 0.875 ± 0.00l#
S4/S2 0.802 ± 0.031 0.852 ± 0.073 1.080 ± 0.143∗ 0.817 ± 0.049
S5/S2 0.656 ± 0.220 0.894 ± 0.109 0.795 ± 0.084 0.766 ± 0.013#
Aorta (dpm/mg tissue) 4305.6 ± 157.9 3402.5 ± 165.8∗ 2725.0 ± 189.0∗ 3913.1 ± 364.7
Cyclosporin and/or cocaine were added before S3 and remained for all the experiment. In each period of stimulation the release fraction was calculated
according to the expression indicated in Section 2. Values represent mean ± S.E.M. of five independent experiments performed in triplicate.
∗ P < 0.05 related to control.
# P < 0.05 related to cyclosporin.
Fig. 2. Drug-induced release of 3H-noradrenaline from rat abdominal aorta segments. Cyclosporin and/or cocaine were added in E1 and E2, except in
control (only with the solvent) and experiments with tyramine. In each period of stimulation the percent of 3H-noradrenaline released was calculated
according to the expression indicated in Section 2. Values represent mean ± S.E.M. of five independent experiments performed in triplicate. ∗P < 0.05
related to control of five experiments. #P < 0.05 related to cyclosporin.
vascular noradrenaline release, 3H-NA loading experiments
were performed. Thus, 3H-NA was released by electrical
stimulation, in the presence of cyclosporin, or by cy-
closporin itself. Both 3H-NA release protocols showed that
cyclosporin increases 3H-NA release. After electrical stim-
ulation, cyclosporin increased both S3/S2 and S4/S2 release
fraction ratios, without changes of the S5/S2 ratio (Table 1).
When cocaine was added to the organ bath, the calculated
fraction ratios became similar to controls. Cocaine alone,
as expected, show a slight increase in 3H-NA release when
compared to control (Table 1). In addition, aorta 3H-NA
contents, after the electrically-induced efflux, were de-
creased, in agreement with the described release results
(Table 1). When the electrical stimulation was replaced by
the direct cyclosporin addition to the organ bath 3H-NA re-
lease also increased (Fig. 2). Once more, cocaine abolished
this cyclosporin effect. These results, from both protocols,
may indicate a cyclosporin tyramine-like effect. In fact,
when cyclosporin was replaced by tyramine results showed
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Fig. 3. Abdominal aorta contents of 3H-noradrenaline (percent of 3H-noradrenaline not released) after the experiments indicated in Fig. 2. Values were
calculated according to the expression indicated in Section 2. Values represent mean ± S.E.M. of five independent experiments performed in triplicate.
∗P < 0.05 related to control of five experiments.
a similar profile (Fig. 2). Moreover, the accumulated percent
of 3H-NA in aorta segments reinforces this behavior (Fig. 3).
All these results seem to suggest that cyclosporin increases
3H-NA release from the sympathetic nervous endings.
The 3H-NA in vitro studies could explain the increase
in noradrenaline plasma levels and the decrease in vascular
noradrenaline contents of cyclosporin-treated rats. However,
the increased adrenaline plasma levels may only be ex-
plained by cyclosporin-induced changes in adrenals. When
the adrenal catecholamine contents were measured, from
cyclosporin-treated animals, no significant changes were
observed when compared to controls (Fig. 4). However,
3,4-dihydroxyphenylacetic acid (DOPAC) values signifi-
cantly increased whereas homovanillic acid (HVA) values
Fig. 4. Adrenal catecholamine contents in the rat after 7 weeks of
treatment with vehicle (control) (n = 10) or with CsA 30 mg/kg per
day (n = 12). Catecholamines [noradrenaline (NA), adrenaline (AD)
and dopamine (DA)] were determined by HPLC-ECD. Data shown are
means± S.E.M.
decreased (Fig. 5). The sum DOPAC + DA (indicator of
synthesis) as well as the DOPAC/DA ratio (indicator of me-
tabolization) showed a significant increase when compared
to control (Table 2).
Fig. 5. Adrenal dopamine and dopamine metabolite contents in rats
after 7 weeks of treatment with vehicle (control) (n = 10) or with
CsA 30 mg/kg per day (n = 12). Catecholamines [dopamine (DA),
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)]
were determined by HPLC-ECD. Data shown are means ± S.E.M.
∗P < 0.05 (vs. corresponding control).
Table 2
Indicators of dopamine (DA) synthesis and degradation
Control (n = 10) Cyclosporin 30 mg/kg
per day (n = 12)
DOPAC/DA (×100) 89.20 ± 11.30 124.40 ± 13.20∗
DOPAC + DA (ng/mg) 9.150 ± 0.491 11.361 ± 0.939∗
Synthesis was evaluated by the sum of DOPAC and DA; degradation was
evaluated by the DOPAC/DA ratio. Values represent mean ± S.E.M.
∗ P < 0.05 related to control.
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4. Discussion
Several mechanisms, including the activation of the sym-
pathetic nervous system, have been proposed to explain the
cyclosporin-induced hypertension. However, like other ex-
planations this hypothesis is also not free of controversy. For
instance, Stein et al. [18] showed in humans an impaired va-
sodilatation rather than sympathetic activation or enhanced
vasoconstriction, which may be an important mechanism for
the alterations of the vascular tone that occurs after long-term
cyclosporin administration. Nevertheless, behind all the con-
troversy that surrounds cyclosporin-induced hypertension
there is one common point: a change in vascular reactivity in
response to several agents, namely noradrenaline. However,
the way of this change is also contradictory in the literature.
In response to noradrenaline or phenylephrine cyclosporin
seems to increase [2–5] or decrease [6–8] vascular contrac-
tion. Several possible mechanisms have been proposed for
the increased sympathetic nerve activity: direct release of
the transmitter induced by cyclosporin from sympathetic
nerves [2] or potentiation of responses to nerve stimulation
[19,20]. According to the hypothesis purposed by Xue et al.
[2], our results also showed an increase in the noradrenaline
release. Since aorta segments are poorly enervated, the ex-
periments were performed with exogenous noradrenaline
(3H-NA). In our experiments, after electrical stimulation the
presence of cyclosporin increased 3H-NA release and de-
creased 3H-NA contents in the vascular segments. It seems
that cyclosporin may increase the noradrenaline release by
acting through the membrane noradrenaline transporter. To
test this hypothesis, the 3H-NA studies were performed
in the presence of cocaine. The results showed that in the
presence of cocaine cyclosporin was unable to induce any
increase on 3H-NA release. As expected, cocaine by itself
increases 3H-NA release. Thus, these results seem to sug-
gest that cyclosporin may have tyramine-like effect. When
the experiments were repeated without electrical stimula-
tion but with addiction of cyclosporin we verified the same
behavior, i.e. an increase in 3H-NA release. Once more this
was similar to the tyramine effect. So, as it happens with
tyramine or amphetamines, cyclosporin may also use the
uptake 1 to enter into the axoplasm. The hypothesis that
cyclosporin could also enter by passive diffusion through
the membrane (like tyramine in high concentrations) is not
probable since cocaine abolish the cyclosporin effect. Once
in the cytoplasm, cyclosporin enters axoplasmic vesicles
and like tyramine or amphetamines decreases the vesicle
pH gradient [21]. This will decrease 3H-NA protonation
and increase 3H-NA release to the cytoplasm and rapidly
from this space to outside. Therefore, cyclosporin seems
to act more upon the noradrenaline transporter than in the
plasma membrane, which is in agreement with contraction
studies in response to potassium where cyclosporin has no
effect (unpublished data from the authors). On the contrary,
observations of Lamb and Webb [19], in rat tail arteries,
indicate that 8.3× 10−6 M cyclosporin appears to be acting
at the level of the plasma membrane potential. The decrease
in the membrane potential increases both release of nora-
drenaline from adrenergic nerve ending and smooth muscle
responses to applied noradrenaline. In our study, electrical
stimulation increases nervous endings stimulation with a
consequent enhancement of noradrenaline transport activ-
ity, as well as the probable cyclosporin tyramine-like effect.
In addition, cyclosporin has no effect on potassium-induced
contraction (data not shown).
In the light of our results, after repeated cyclosporin
treatment vessels were expected to be depleted of cat-
echolamines. Few works have addressed the effect of
cyclosporin on catecholamine tissue contents. In 1995,
Pestana et al. [22] reported an accumulation of DA and
DOPAC in the rat kidney tissue after 14 days of treatment
with 50 mg/kg per day cyclosporin. In the present work,
after 7 weeks of cyclosporin treatment a decrease of the
abdominal aorta catecholamine contents were observed.
These data are in agreement with our hypothesis that cy-
closporin may have a tyramine-like effect. This effect could
also partially justify the increase in plasma catecholamines
previously reported [14]. The increase in plasma adrenaline
found before [14] is difficult to explain with this hypoth-
esis, since plasma adrenaline levels reflect the amounts of
adrenaline synthesized and released by adrenal glands. We
found no significant changes in adrenaline contents in the
adrenals of cyclosporin-treated animals as compared with
the controls. The same results in adrenals were found as re-
gards the other catecholamines assayed (noradrenaline and
dopamine). Despite this, on analyzing the dopamine synthe-
sis/degradation ratio, as measured by dopamine metabolite
levels, and the relations DOPAC + DA and DOPAC/DA
some differences were observed. The results obtained in
the group of rats treated with 30 mg/kg per day cyclosporin
suggest an increase in dopamine synthesis. For some reason,
however, this dopamine (or at least not all the dopamine
synthesized) was unable to enter neuronal vesicles to be
metabolized into noradrenaline and adrenaline. Some of it
was converted into DOPAC outside the vesicles leading to
the verified increase in DOPAC levels. These findings are
in agreement with the results obtained by Pestana et al.
[22] in rat kidney tissue after 50 mg/kg per day cyclosporin
treatment. According to our results, it would appear that
vesicles have some difficulty in incorporating dopamine.
A possible reason could be the hypothesis discussed above
that cyclosporin may have a direct effect on catecholamine
transport across membranes. Moreover, in the adrenals of
this group of rats a decrease in HVA levels was also ob-
served, suggesting that this concentration of cyclosporin
might also interfere in the conversion of DOPAC to HVA,
inhibiting extraneuronal uptake and subsequent metaboliza-
tion by COMT (catechol-o-methyltransferase), or directly
inhibiting DOPAC o-methylation.
In spite of the absence of differences in adrenals cat-
echolamine contents we could not exclude the fact that
cyclosporin could increase both adrenal catecholamine
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synthesis and release, since the sum of DA and DOPAC
were increased.
It was been hypothesized that cyclosporin-induced hyper-
tension could be caused by renal and other sub-diaphrag-
matic afferent activation, which reflexively activates efferent
sympathetic, nerve activity and therefore causes neurogenic
vasoconstriction [23,24]. This could be also be an explana-
tion for our in vivo results. However, we also demonstrated
that more than this effect on the activation of sympathetic
nerve activity, cyclosporin has also a direct effect over the
sympathetic nervous endings.
In conclusion, our results suggest that cyclosporin in-
crease the noradrenaline release from sympathetic nervous
endings, probably by interfering on the catecholamine trans-
port across membrane rather than by an action on the plasma
membrane potential. This fact may explain the increase in
catecholamine plasma levels and the consequent arterial
hypertension, as well as the increase in adrenal DOPAC.
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